University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study

Simple item page
dc.contributor.authorSanghavi, Ria
dc.contributor.authorPana, Tiberiu A.
dc.contributor.authorMamayusupova, Hulkar
dc.contributor.authorMaidment, Ian
dc.contributor.authorFox, Chris
dc.contributor.authorBoekholdt, S Matthijs
dc.contributor.authorMamas, Mamas A
dc.contributor.authorWareham, Nicholas J.
dc.contributor.authorKhaw, Kay Tee
dc.contributor.authorMyint, Phyo Kyaw
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2022-06-14T11:57:01Z
dc.date.available2022-06-14T11:57:01Z
dc.date.issued2022-07-01
dc.descriptionAcknowledgements: We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We would also like to acknowledge the principal investigators and staff of the EPIC-Norfolk study. Funding The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) was funded by the Medical Research Council, Grant number (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK, Grant number (C864/A14136).en
dc.description.statusPeer revieweden
dc.format.extent10
dc.format.extent1361751
dc.identifier212639136
dc.identifierab23a5c2-d777-4b10-89e3-f69edc0bf4f3
dc.identifier35118716
dc.identifier85125367286
dc.identifier.citationSanghavi, R, Pana, T A, Mamayusupova, H, Maidment, I, Fox, C, Boekholdt, S M, Mamas, M A, Wareham, N J, Khaw, K T & Myint, P K 2022, 'Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort study', British Journal of Clinical Pharmacology, vol. 88, no. 7, pp. 3297-3306. https://doi.org/10.1111/bcp.15261en
dc.identifier.doi10.1111/bcp.15261
dc.identifier.iss7en
dc.identifier.issn0306-5251
dc.identifier.otherORCID: /0000-0002-1423-8111/work/107908265
dc.identifier.otherORCID: /0000-0003-3852-6158/work/163198880
dc.identifier.urihttps://hdl.handle.net/2164/18711
dc.identifier.vol88en
dc.language.isoeng
dc.relation.ispartofBritish Journal of Clinical Pharmacologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectAnticholinergicsen
dc.subjectfibrinogenen
dc.subjectC-Reactive Proteinen
dc.subjectTumour Necrosis Factor-alphaen
dc.subjectInterleukin-6en
dc.subjectcardiovascular diseasesen
dc.subjectR Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectMR/N003284/1en
dc.subjectMC-UU_12015/1en
dc.subjectCancer Research UKen
dc.subjectC864/A14136en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleHigher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPIC-Norfolk prospective population-based cohort studyen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sanghavi_etal_Higher_anticholinergic_burden_VOR.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Download

Collections

All research